Christopher Boerner

Chief executive: Bristol Myers Squibb Co. (1 Nov 2023 to present)

9commitments announced

4with a clear outcome

4met on time

–rate shown after 15 outcomes

Commitments are credited to the chief executive in office on the day they were announced. Where a deadline fell after the leader left, the entry is marked. Sources for each leadership change: Bristol Myers Squibb Co. filing.

Commitments announced under Christopher Boerner

Bristol Myers Squibb Co.announced 31 Jul 2025	Close the license of OncoACP3 from Philochem AG to RayzeBio, Inc	Met30 Sep 2025
Bristol Myers Squibb Co.announced 24 Apr 2025	Report pivotal data for RYZ101 in first-line extensive-stage small cell lung cancer	Open31 Dec 2026
Bristol Myers Squibb Co.announced 31 Oct 2024	Report Phase 3 data readout for adjunctive schizophrenia (KarXT/Cobenfy) in 2025	Being checked31 Dec 2025
Bristol Myers Squibb Co.announced 31 Oct 2024	Report Phase 3 data readout for Alzheimer's psychosis (KarXT/Cobenfy) in 2026	Open31 Dec 2026
Bristol Myers Squibb Co.announced 25 Apr 2024	Initiate a Phase 3 trial of Opdualag plus chemotherapy in non-small cell lung cancer	No record found31 Dec 2024
Bristol Myers Squibb Co.announced 8 Jan 2024	Report ODYSSEY-HCM Phase 3 data for symptomatic nHCM with Camzyos	Met31 Dec 2025
Bristol Myers Squibb Co.announced 22 Dec 2023	Launch KarXT in the U.S. for the treatment of schizophrenia in adults	Met31 Dec 2024
Bristol Myers Squibb Co.announced 22 Dec 2023	Report data from the registrational clinical trial for KarXT as adjunctive treatment	Met31 Dec 2025
Bristol Myers Squibb Co.announced 22 Dec 2023	Report data from the registrational clinical trials for KarXT for Alzheimer’s disease psychosis	Open31 Dec 2026

Is this record wrong, or are you Christopher Boerner? Add a statement or ask for a correction.

Commitments announced under Christopher Boerner

The Deadline Report